| Autor: |
Hemminki, A., Mecklin, J.P., Jarvinen, H., A. Aaltonen, L., Joensuu, H. |
| Zdroj: |
Gastroenterology; October 2000, Vol. 119 Issue: 4 p921-928, 8p |
| Abstrakt: |
Background & Aims: Adjuvant 5-fluorouracil(5-FU)-based chemotherapy is standard treatment for stage C colorectal cancer (CRC). Approximately 12% of CRCs are characterized by microsatellite instability (MSI), a hallmark of a DNA mismatch repair defect. We investigated the safety of adjuvant 5-FU-based chemotherapy for MSI^+ CRC and compared the prognosis of MSI^+ and MSI^-- CRC patients receiving adjuvant therapy. Methods: Previously, a prospective series consisting of 1044 consecutive CRCs has been collected and the MSI status of each sample determined. Patients with stage C cancer who had received adjuvant chemotherapy (n = 95) were followed up for 7-63 months (median, 31 months) after surgery. Results: No unexpected or serious adverse effects were observed when 5-FU-based chemotherapy was used as adjuvant treatment for MSI+ CRC. Three-year recurrence-free survival was 90% and 43% in the MSI+ (n = 11) and MSI^- (n = 84) groups, respectively (P = 0.020). Conclusions: Adjuvant 5-FU-based chemotherapy is feasible for both MSI^+ and MSI^- CRCs, and patients with MSI^+ CRC who receive adjuvant therapy have an excellent prognosis. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
